Milan, Italy

Carlos Passarotti

This inventor holds 1 USPTO granted patent. Top assignee: Prodotti Formenti S.r.l.. Active years: 1991.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Carlos Passarotti: Innovator in Pharmaceutical Compositions

Introduction

Carlos Passarotti is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of oral compositions. His work focuses on enhancing the absorption and effectiveness of pharmaceutical compounds.

Latest Patents

Carlos Passarotti holds a patent for "Oral pharmaceutical compositions containing dextrophan salts." This invention highlights the use of dextrorphan salts combined with polycarboxylic organic acids, which are effectively absorbed through the oral route. The formulation is designed to be suitable for oral administration, making it a valuable addition to pharmaceutical applications.

Career Highlights

Throughout his career, Carlos has demonstrated a commitment to innovation in the pharmaceutical industry. His work at Prodotti Formenti S.r.l. has allowed him to explore new avenues in drug formulation and delivery. His patent reflects his dedication to improving patient outcomes through effective medication.

Collaborations

Carlos has collaborated with esteemed colleagues such as Antonio Fossati and Mauro Valenti. These partnerships have fostered a creative environment that encourages the development of groundbreaking pharmaceutical solutions.

Conclusion

Carlos Passarotti's contributions to the field of pharmaceuticals, particularly through his patent on oral pharmaceutical compositions, underscore his role as an innovator. His work continues to influence the industry and improve the efficacy of drug delivery systems.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…